SOPHiA GENETICS (SOPH) director sells at ~$8.68, keeps 103K shares

Rhea-AI Filing Summary

SOPHiA GENETICS SA (SOPH) director Kathy L. Hibbs reported selling 6,250 Ordinary Shares on 2026-08-25 in an open market or private transaction at a weighted average price of $8.6773 per share, with individual trade prices ranging from $8.31 to $8.83. The sale was made pursuant to a duly adopted Rule 10b5-1(c) trading plan, and following this transaction she directly owns 103,242 Ordinary Shares.

Insider Trade Summary 10b5-1

Net Seller: 6,250 shares

Net Sell 1 txn

Insider HIBBS KATHY L

Role Director

Sold 6,250 shs ($54K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F2	6,250	$8.6773	$54K

Holdings After Transaction: Ordinary Shares — 103,242 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.31 to $8.83 inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 6,250 Ordinary Shares Weighted average sale price: $8.6773 per share Sale price range: $8.31–$8.83 per share +1 more

4 metrics

Shares sold 6,250 Ordinary Shares Non-derivative sale reported on 2026-08-25

Weighted average sale price $8.6773 per share Weighted average for shares sold on 2026-08-25

Sale price range $8.31–$8.83 per share Range of individual transaction prices within the reported sale

Shares owned after transaction 103,242 Ordinary Shares Direct ownership of Kathy L. Hibbs following the sale

Key Terms

Rule 10b5-1(c), weighted average price, Ordinary Shares, non-derivative

4 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Ordinary Shares financial

"security_title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

non-derivative financial

"transaction_type: non-derivative"

FAQ

What insider transaction did SOPH director Kathy L. Hibbs report on this Form 4 for SOPH?

Kathy L. Hibbs reported a sale of 6,250 Ordinary Shares of SOPHiA GENETICS SA (SOPH) on 2026-08-25. The transaction was coded as a sale in an open market or private transaction and was conducted under a Rule 10b5-1(c) trading plan.

At what price were the SOPH shares sold in Kathy L. Hibbs’ Form 4 transaction?

The reported price is a weighted average of $8.6773 per share. The shares were sold in multiple trades at prices ranging from $8.31 to $8.83 per share, inclusive, as disclosed in the Form 4 footnote.

How many SOPH shares does Kathy L. Hibbs own after this reported sale?

After the reported sale, Kathy L. Hibbs directly owns 103,242 Ordinary Shares of SOPHiA GENETICS SA (SOPH), according to the post-transaction ownership figure disclosed in the Form 4.

Was the SOPH insider sale by Kathy L. Hibbs made under a Rule 10b5-1 plan?

Yes. The Form 4 states that the transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). The filing’s Rule 10b5-1 checkbox is also affirmed, indicating the sale followed a pre-established plan.

What type of security did Kathy L. Hibbs trade in this SOPH Form 4 filing?

The transaction involved Ordinary Shares of SOPHiA GENETICS SA (SOPH). The filing classifies the transaction as involving a non-derivative security rather than options or other derivative instruments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/26/2026 - 04:06 PM Accepted by SEC EDGAR 08/26/2026 - 04:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HIBBS KATHY L

(Last) (First) (Middle)

C/O SOPHIA GENETICS INC.

401 PARK, 5TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/25/2026		S		6,250(1)	D	$8.6773(2)	103,242	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.31 to $8.83 inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-Fact for Kathy L. Hibbs	08/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)